

Cover Story
By Paul Goldberg and Tessa Vellek
Some of the questions that landed the AstraZeneca drug Olaparib (lynparza) before the FDA Oncologic Drugs Advisory Committee were classic:
By Tessa Vellek
In Brief
Trending Stories
- Otis Brawley looks back on a year of great science and greater challenges
- Mikaela Naylon Give Kids a Chance Act nixed by Senate
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- Twitter star Vinay Prasad retires @VinayPrasadMD
- AI will determine Medicare prior authorizations in six states under new pilot program
- Elisa Rodriguez named first chief diversity and equity officer for faculty at Roswell Park











